Opens in a new tab

La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 13 March 2026)

Date13 March 2026
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionRevocation Action
Case number(s)UPC_CFI_927/2025
Registry referenceUPC-CFI-0000927/2025
PartiesLa Siddhi Consultancy Limited v. Athena Pharmaceutiques SAS, Substipharm

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 13 March 2026 (UPC_CFI_927/2025), the Milan Central Division, ordered La Siddhi Consultancy, the UK claimant in the revocation action against unitary patent EP 3 592 333, to provide within six weeks security of EUR 75,000 for the costs of Athena Pharmaceutiques and Substipharm, which had sought EUR 112,000. The order shows that security follows an estimate of first-instance costs rather than the ceiling, and that SME status must be shown with figures.

Question

Does the claimant’s financial position justify security for costs under Rule 158 RoP, in what amount and within what time, and does its SME status warrant a reduction?

Decision

The test is whether there is a legitimate and real concern that a costs order may not be recovered, in light of the claimant’s own position. The group’s position is irrelevant absent a guarantee (paragraph 14). The undisputed 2024 balance sheet leaves a margin of about EUR 31,000 between current assets and current liabilities, and the claimant showed no improvement (paragraphs 20 to 24). For a value in dispute of EUR 1 million the ceiling is EUR 112,000, but the Division set EUR 75,000 in the absence of a costs estimate, excluding appeal costs (paragraphs 25 to 28). The declaration filed gave no figures on headcount, turnover or balance sheet, so micro-enterprise status was not established (paragraph 29). Six weeks is a reasonable time limit (paragraph 31), and leave to appeal was granted.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 69(1) and (4) and 73
Rules of Procedure
Rules 158.1, 158.4, 158.5, 171.2, 220.2, 224.1(b), 355 and 370.8
Other texts
Commission Recommendation 2003/361/EC, Annex, Art. 2(3)
Case law cited
Syntorr v Arthrex, Court of Appeal, 18 February 2026, Chint v JingAo, Court of Appeal, 9 July 2025, Audi v NST, Court of Appeal, 17 September 2024, Suinno v Microsoft, Court of Appeal, 12 July 2025, Aarke v SodaStream, Court of Appeal, 29 November 2024, Visibly v Easee, Hamburg Local Division, 30 May 2025, BfexaQC v NVIDIA, Munich Local Division, 28 October 2025 (UPC_CFI_729/2025)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Revocation action.

Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_927/2025 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 13 March 2026 La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 13 March 2026) Revocation Action · UPC_CFI_927/2025
  2. 19 May 2026 La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 19 May 2026) Revocation Action · UPC_CFI_927/2025

    Le régime « external eyes only » demandé pour un accord produit au soutien de la qualité à agir est refusé. L'accès est ouvert, côté défenderesses, aux représentants externes, à leur directeur juridique et à un conseil indien.

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
La Siddhi Consultancy doit fournir sous six semaines une garantie de 75 000 euros pour les frais des défenderesses, sa situation financière faisant craindre un défaut de recouvrement et son statut de PME n'étant pas établi. L'autorisation d'appel est accordée.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 592 333Mentioned in the analysis (role not qualified)
Also mentioned in 3 other decision(s): La Siddhi Consultancy v Athena Pharmaceutiques (CoA, 1 June 2026) · La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 19 May 2026) · La Siddhi Consultancy v Athena Pharmaceutiques (CoA, 14 April 2026)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.